@FierceMedDev: Edwards wins Japanese nod for next-gen Sapien valve. Story | Follow @FierceMedDev
@DamianFierce: Miss our ADA 2013 coverage? Diabetes news from Medtronic and J&J. | Follow @DamianFierce
@MichaelGFierce: FDA approved Lombard's Aorflex delivery system, used with its Aorfix stent. Looking to launch this year. More | Follow @MichaelGFierce
> Fresh off raising $100 million, Valeritas is touting study results showing patients using its V-Go insulin delivery device reported improved glycemic control compared to other technologies. News
> Quest Diagnostics ($DGX) has completed its buyout of Humana's ($HUM) toxicology and clinical laboratory business. More
> In a study of 36 patients, Sorin's Reply 200 pacemakers beat out standard methods in measuring the severity of sleep apnea. Results
> Exact Sciences ($EXAS) wrapped up its stock offering, raising a net $73.4 million to market its Cologuard cancer test. Item
> Good Start Genetics has received approval to launch its sequencing-based carrier screening test in New York. News
Biotech News
@FierceBiotech: Troubled AstraZeneca models a new industry R&D tie-up as setbacks mount. Story | Follow @FierceBiotech
@JohnCFierce: Sandoz bulls ahead with full slate of PhIII biosimilar studies. News | Follow @JohnCFierce
@RyanMFierce: PFE shares software for biotech drug research to pharma rivals like GSK, Roche and others. Story | Follow @RyanMFierce
@EmilyMFierce: Our special ADA 2013 issue, via @RyanMFierce: Here | Follow @EmilyMFierce
> FDA clamps partial hold on Cell Therapeutics trial after patient dies. News
> KKR scoops up global CRO PRA in $1.3B buyout deal. More
> Sanofi chief threatens R&D cutbacks unless EMA retreats on open data plan. News
Pharma News
@FiercePharma: CX, that's 7 trials of 5 biosims for Novartis ... Novartis starts PhIII trial of biosimilar of Amgen's Enbrel. Report | Follow @FiercePharma
@EricPFierce: Has down-home Paula become the 'Deen' of bad publicity for Novo Nordisk? Item | Follow @EricPFierce
@CarlyHFierce: Shoutout to FierceBiotech in First Manhattan's letter to Vivus shareholders. Letter | Story | Follow @CarlyHFierce
> Russia's Pharmstandard eyes buyers for $2.5B OTC drug business. More
> Proxy challenger scoffs at Vivus as annual meeting nears. Report
> Reported Form 483 may explain Ranbaxy not getting Diovan to market. Story
CRO News
> Icon, Clintec launch grad programs for clinical research. Article
> CRS signs on with Bayer for early trials. Story
> Novotech reaches into Hong Kong, Philippines. News
> inVentiv taps PatientsLikeMe for trial recruitment. Report
Biotech IT News
> Roche designs online software for sequencing business. Story
> FDA taps India's GVK for database support in drug recycling. More
> Pfizer shares software for biotech drug research with pharma rivals. News
> Scientists follow 'Facebook' strategy to corral cancer Big Data. Story
> PatientsLikeMe seals CRO deal for online trial recruitment. Article